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ABSTRACT
Transfusion of blood products should 
improve tissue oxygenation and reduce 
negative consequences of anaemia. At the 
same time, adverse effects of transfusion, 
such as infections, immunologic reactions 
and mistransfusion, could be deleterious. 
Most transfusion guidelines suggest look-
ing at the combination of haemoglobin or 
haematocrit levels in addition to clinical 
signs in the decision making process for a 
blood transfusion. The problem with such 
indications is that the clinical evaluation 
may be misleading in severely ill patients 
and haemoglobin levels that impair oxy-
gen delivery cannot be determined easily. 
Many studies attempted to establish more 
convenient parameters, such as oxygen 
saturation from mixed and central ve-
nous blood, tissue oxygen extraction and 
other methods. Although the results from 
these studies are conflicting, it appears that 
global oxygenation parameters are a good 
indicator for a blood transfusion in some 
categories of critically ill patients.
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INTRODUCTION
According to the World Health Organisa-
tion, anaemia represents a condition of de-
creased haemoglobin (Hgb) concentration 
(<12 g/dL in women and <13 g/dL in men). 
In a critically ill population, two-thirds of 
patients match this criteria. The aetiol-
ogy of anaemia in critical illness relates to 
haemodilution, bleeding, blood sampling, 
increased haemolysis, nutritional deficien-
cies, blunted erythropoietin production, 
abnormalities in iron metabolism, etc. (1, 
2) The ability to develop compensatory 
mechanisms that would assure metabolic 
needs, will determine the tolerance of anae-
mia in each patient. These mechanisms in-
clude: blood flow redistribution, increased 
cardiac output (CO) and increased oxygen 
extraction ratio (ERO2), among others. (3, 
4) Negative effects of anaemia are a result 
of impaired tissue oxygen delivery (DO2) 
that may increase the risk of morbidity and 
mortality in critically ill patients, especially 
at Hgb levels below 5-6 g/dL. (5) The trans-
fusion of blood products should improve 
tissue oxygenation and reduce negative 
consequences of anaemia. At the same 
time, the adverse effects of transfusion, 
such as infections, immunologic reactions 
and mistransfusion, could be deleterious. 
(4) According to the American Society of 
Anesthesiologists (ASA), the Society of 
Thoracic Surgeons (STS) and the Society of 
Cardiovascular Anesthesiologists (SCA), 
red blood cells (RBCs) should be adminis-
tered when DO2 decreases below a critical 
level or when euvolemic patients develop 
complications from disturbed tissue oxy-
genation. (1, 6)
HAEMOGLOBIN/HAEMATOCRIT 
THRESHOLDS FOR BLOOD TRANSFU-
SIONS IN CRITICAL ILLNESS
Although the main goal of RBCs transfu-
sions is to improve oxygen delivery and 
tissue utilisation, a number of intensivists 
still use Hgb and haematocrit (Htc) levels 
as an exclusive transfusion trigger. Since a 
critical Hgb level that impairs DO2 cannot 
be easily determined, such clinical practice 
is questionable. (7 - 9) The patient’s age, 
primary diagnosis and clinical symptoms, 
volume status, aetiology and duration of 
anaemia, surgery duration, ongoing bleed-
ing, compensatory mechanisms, pulmo-
nary, cardiovascular and cerebrovascular 
comorbidities, and signs of poor end organ 
perfusion or ischaemia, should significant-
ly affect decisions for transfusion therapy. 
(1, 3, 6, 7, 9) Throughout the years, Hgb/
Htc thresholds for RBCs transfusions have 
decreased considerably, without adverse 
effects and worsening clinical outcomes. 
(10, 11) The results of the TRICC study 
demonstrated that 30 day mortality, fre-
quency of myocardial infarction, acute 
respiratory distress syndrome (ARDS) and 
pulmonary oedema were reduced when 
RBCs were administered at lower Hgb lev-
els or when they were not administered at 
all. (11) Some other studies of critically ill 
patients (ABC, CRIT), linked transfusion 
therapy and the number of transfused units 
to a higher risk of mortality and prolonged 
intensive care unit (ICU) and hospital 
stays. In contrast, similar mortality rates 
between transfused and nontransfused pa-
tients were found in 1,040 septic patients 
who received a blood transfusion in the 
observational European SOAP study. In 
the transfusion group a higher 30-day sur-
vival rate was noticed. (12) In the FOCUS 
study of Carson et al. on high risk elderly 
patients with underlying cardiovascular 
disease subjected to the hip surgery, a lib-
eral RBCs transfusion strategy (Hgb≥100 
g/L), in comparison to restrictive strategy 
(Hgb≤80 g/L or symptomatic anaemia), 
did not affect mortality or reduce inability 
to walk independently on a 60-day follow-
up, nor did it affect in-hospital morbidity. 
The study results did not support the hy-
potheses that a blood transfusion induces 
long-term immunosuppression that is 
severe enough to increase the mortal-
ity rate by more than 20–25%. (13) On a 
study population of 73,067 patients with 
a non-ST segment elevation myocardial 
infarction subjected to cardiac catheterisa-
tion, Hanna et al. reported that lower Hgb 
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concentrations were associated with more 
extensive coronary artery disease, less use 
of revascularisation, evidence-based thera-
pies and a higher in-hospital mortality 
(7% increase for each 1g/dL decrease in 
Hgb lower than 15 g/dL). (14) According 
to the Eastern Association for the Surgery 
of Trauma and the American College of 
Critical Care Medicine of the Society of 
Critical Care Medicine, RBCs transfusions 
are clearly indicated for the treatment of 
hemorrhagic shock, particularly in pa-
tients who have reached critical DO2. The 
efficacy of RBCs transfusions in haemody-
namically stable trauma and critically ill 
patients with anaemia has not been dem-
onstrated in most clinical settings. RBCs 
transfusions should be considered in pa-
tients on mechanical ventilation, trauma 
patients after their initial stabilisation and 
in patients with stabile cardiac disease be-
low a Hgb level of 7 g/dL, which is equally 
effective as transfusions below a Hgb level 
of 10 g/dL. In patients with acute coronary 
syndrome (ACS), RBCs administration 
may have positive effects at Hgb levels be-
low 8 g/dL. In septic patients, RBCs trans-
fusions must be assessed individually since 
optimal transfusion triggers in sepsis are 
not known and there is no clear evidence 
that transfusion increases tissue oxygena-
tion. In patients at risk for acute lung in-
jury or ARDS, the administration of RBCs 
should be avoided. RBCs should not be 
used as a method of weaning patients from 
mechanical ventilation. In the absence 
of acute bleeding, transfusions should be 
given as single units. (9) The transfusion 
guidelines from the Croatian Medical As-
sociation and the Croatian Society for 
Quality Improvement in Health Care sug-
gest Hgb 7.0 g/dL as a level at which trans-
fusion therapy must be started in critically 
ill patients. (15) The guidelines of the Eu-
ropean Society of Anaesthesiology suggest 
a Hgb concentration of 7.0 – 9.0 g/dL dur-
ing active perioperative bleeding. (16) ASA 
guidelines suggest a Hgb concentration 
from 6 to 10 g/dL, depending on a patient’s 
clinical status. Transfusions for patients 
undergoing cardiopulmonary bypass is in-
dicated at a Hgb concentration of 6.0 g/dL. 
For patients older than 65 and for patients 
with chronic cardiovascular or respiratory 
diseases, transfusions are justified at a Hgb 
concentration of 7,0 g/dL. For stable pa-
tients with a Hgb concentration between 
7 and 10 g/dL, the benefit of transfusions 
is unclear. In patients with active bleed-
ing, transfusions are recommended after 
a blood loss higher than 1,500 mL or 30% 
of blood volume. Rapid blood loss without 
immediate control warrants a blood trans-
fusion. (1) The American STS and SCA 
guidelines suggest transfusions in cardiac 
patients at a Hgb concentration of 6 g/dL, 
as this can be lifesaving. Haemoglobin of 
7 g/dL represents a reasonable transfusion 
threshold in most cardiac postoperative 
patients. Transfusions for Hgb levels above 
10 g/dL is not suggested. (6) Because of 
insufficient primary compensatory mecha-
nisms, damaged ventricular function and 
oxygen transport, most guidelines rec-
ommend higher Hgb concentrations as 
a transfusion indication in patients with 
ACS. Also, most transfusion guidelines 
suggest the use of a clinical assessment in 
combination with the Hgb concentration. 
The problem with such recommendations 
is that a clinical evaluation may be mis-
leading in severely ill and unstable patients.
GLOBAL OXYGENATION PARAM-
ETERS IN CRITICAL ILLNESS
Considering the fact that blood loss esti-
mation, intravascular volume and clini-
cal symptoms are not always adequate 
(and that there is little scientific evidence 
to point to a specific Hgb/Htc level as an 
optimal transfusion trigger), many studies 
tried to establish more convenient param-
eters. Most studies directed their efforts 
to global oxygenation parameters, such as 
oxygen saturation from mixed and central 
venous blood (SVO2, ScVO2), DO2, oxy-
gen consumption (VO2) and ERO2. SVO2 
indicates the relation between global VO2 
and DO2. Tissue dysoxia, indicated by de-
creased VO2 depending on DO2, usually 
becomes evident at SVO2 levels of 40-50%. 
If ERO2 is disturbed, tissue dysoxia may 
be evident at higher SVO2 levels. SVO2 
depends on Hgb concentrations, CO, VO2 
and arterial oxygen saturations (SaO2). It 
should be a key factor in determining the 
amount of blood loss a critically ill patient 
can tolerate. (17) Studies on animal mod-
els with acute, normovolemic haemodilu-
tion, demonstrated that a Hgb concentra-
tion of 4 g/dL represents the level when 
VO2 starts to decline, which corresponds 
to SVO2 of 44% and ERO2 of 57%. (18, 
19) Most investigators used SVO2 and 
calculated ERO2 as transfusion indica-
tors. Keeping in mind the risks from pul-
monary artery catheterisation, the use of 
these parameters in everyday clinical prac-
tice may be difficult. (20-26) Considering 
the fact that most critically ill patients in 
medical or surgical ICUs do not have a 
pulmonary artery catheter inserted, or 
it is inserted for a short period of time, a 
question can be raised whether ScVO2 and 
ScVO2 derived ERO2 may be used as rel-
evant transfusion indicators. SVO2 reflects 
the relation between DO2 and VO2 in the 
upper and lower parts of the body and the 
heart. ScVO2 reflects the balance between 
DO2 and VO2 in the cranial part of the 
body and the brain. Although in normal 
conditions and healthy individuals SVO2 
is higher than ScVO2 (2-5%), this rela-
tion may change in shock of any aetiology, 
severe sepsis, cardiac decompensation, 
head injury, etc. In these conditions (due 
to a blood flow redistribution in the up-
per parts of the body, decreased splanch-
nic and renal circulation and increased 
ERO2) ScVO2 may outmatch SVO2 by 
up to 20% . (27-31) The use of individual 
ScVO2 and ERO2 values as transfusion 
indicators in these conditions is question-
able. In the most common situations in the 
ICU, when SaO2 is near 100%, ERO2 may 
be calculated from the SaO2 and SVO2 
difference, without a need for VO2 and 
DO2 measurements. (31, 33, 34) When 
anaemia results in DO2 reduction, ERO2 
of 50% represents an indirect indicator of 
tissue oxygen deficit and may be used as a 
transfusion trigger. (24) Studies that com-
pared ScVO2 and SVO2 in various clini-
cal situations have still not provided reli-
able answers on the question of whether or 
not both of these parameters can be used 
for the purpose of triggering transfusion 
therapy. As a result of blood flow redistri-
bution, regional impairment of tissue oxy-
genation and microcirculation in critically 
ill patients, the various outcomes of these 
studies are often inconclusive. Therapeutic 
procedures in the ICU (oxygenotherapy, 
assisted ventilation, administration of 
fluids, inotropes, anaesthetics, analgetics, 
sedatives etc.) additionally contribute to 
a disproportionality between ScVO2 and 
SVO2. (28, 29, 30) Although ScVO2 and 
SVO2 do not correlate completely, in the 
2012 Surviving Sepsis Campaign Guide-
lines, both of these values are considered 
equivalent, and targets of 70% and 65% re-
spectively are recommended in the begin-
ning of septic resuscitation. (35) In a study 
by Rivers et al., ScVO2 was used during 
early goal-directed therapeutic interven-
tions to restore a balance between DO2 
and VO2 in patients with severe sepsis and 
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septic shock. (36) On animals, and later on 
high risk critical patients, Reinhart et al. 
demonstrated a good correlation between 
ScVO2 and SVO2 in conditions such as 
bleeding, fluid resuscitation, hypoxia, nor-
moxia and hyperoxia. According to the 
authors, ScVO2 may confidently predict 
acute changes in VO2/DO2 relations, i.e. 
monitor trends in DO2 and VO2. (31, 37) 
Sekkat et al. and Dueck et al. had similar 
conclusions on cardiac and neurosurgical 
patients. They found significant differences 
in the numerical ScVO2 and SVO2 values, 
but also they found trends between these 
parameters that correspond to various 
haemodynamic conditions which can be 
used in clinical decision making. (38, 39) 
In a study on 53 surgical and medical pa-
tients, Chawla et al. concluded that ScVO2 
was not a reliable substitute for SVO2, and 
that calculating VO2 in this way may cause 
serious errors. (40) In a study on 20 pa-
tients in hemorrhagic or septic shock, Ho 
et al. demonstrated that changes in ScVO2 
and SVO2 do not accompany each other 
and that this distinction increases when 
SVO2 falls below 70%. (41) In a study on 
20 patients, Lorentzen et al. found that 
ScVO2 and SVO2 were not comparable in 
patients undergoing aortic valve replace-
ment. In patients subjected to coronary 
artery bypass graft (CABG) procedures, 
ScVO2 may be used as a SVO2 substitute, 
although absolute values were not com-
pletely the same. Lower SaO2 (<92%), re-
duced Hgb levels and low CO, increased 
this disproportion. (42) Elsherbeny et al. 
found that there is poor agreement be-
tween ScVO2 and SVO2 regardless of 
type of surgery, changes in CO and type 
of pharmacological support. ScVO2 values 
above 70% could reliably predict normal 
SVO2, but ScVO2 values below 70% could 
not reliably predict inadequate SVO2. (43)
GLOBAL OXYGENATION PARAM-
ETERS AS INDICATORS FOR BLOOD 
TRANSFUSION
In a study by Paone et al. on 100 cardio-
vascular patients, SVO2 of 55% was used 
as a transfusion trigger. The study results 
showed that blood transfusions were sig-
nificantly reduced in comparison to the 
amount of blood that would be transfused 
if traditional triggers were used. (20) On 
60 high risk, surgical, haemodynamically 
stable patients, Adamczyk et al. assessed 
the ScVO2 value for a decision for blood 
transfusions in comparison to the criteria 
of the French guidelines for blood trans-
fusions in critically ill patients, which is 
based on a consensus by the French So-
ciety of Intensive Care Medicine (SLRF). 
The French guidelines suggest administra-
tion of RBCs according to Hgb levels and 
the associated clinical state of the patient 
(10 g/dL – ACS, 9 g/dL – ischemic heart 
disease, stable heart failure, 8 g/dL > 75 
years, severe sepsis, 7 g/dL – other critical-
ly ill patients). In the study, patients were 
retrospectively divided into two groups 
based on ScVO2 values (< or >70%) prior 
to transfusion therapy. Each group was 
additionally divided in two subgroups, 
depending on whether SLRF criteria were 
matched. Although the transfusions sig-
nificantly increased Hgb levels in all pa-
tients, ScVO2 was significantly increased 
only in patients with pretransfusion levels 
below 70%. Thirteen patients of 20 that 
were transfused contrary to SLRF recom-
mendations had an ScVO2 < 70%, and 
regarding the VO2/DO2 relationship they 
seemed to benefit from the blood transfu-
sion. 54.5% of the patients that received a 
blood transfusion according to the SRLF 
criteria had an ScVO2 ≥ 70%, which im-
plies that the VO2/DO2 relation had been 
adequate and that the patients were trans-
fused in excess. (21) Considering physi-
ologic and pathophysiologic mechanisms 
for the oxygen exchange at the cellular 
and tissue levels, ERO2 could be used as 
the best indicator for transfusion therapy. 
(22-26, 44, 45) A reduction in ERO2 fol-
lowing the administration of RBCs should 
point out that a blood transfusion was jus-
tified. Bashir et al. compared cerebral and 
peripheral oxygen saturation in patients 
subjected to autologous blood transfusions 
during abdominal aortic aneurysm repair. 
In the post-transfusion group of patients 
with decreased ERO2, a statistically sig-
nificant increase in cerebral oxygen satu-
ration, Hgb concentration, oxygen partial 
pressure and SVO2 was noticed. (44) On 
an animal model, Wilkerson et al. tried to 
determine whether global ERO2 reflects 
disturbed myocardial metabolism during 
acute, normovolemic anaemia. The left 
ventricular metabolism (arterial-coronary 
sinus lactate) was compared to ERO2. The 
authors concluded that ERO2 could be a 
valid indicator of myocardial metabolism 
in anaemia and that significant myocar-
dial lactate production starts when global 
ERO2 exceeds 50%, which may serve as 
an indication for a blood transfusion. (22) 
On animals subjected to critical left as-
cending coronary artery stenosis, Levy et 
al. demonstrated that cardiac failure oc-
curs at higher Htc levels. In the presence 
of limited coronary vascular reserve, the 
whole body ERO2 greater than 50% may 
serve as a valid indicator of myocardial 
metabolism in anaemia, and may be a use-
ful guide to transfusion therapy. (23) In the 
study of Orlov et al. on patients subjected 
to cardiopulmonary bypass (CPB) proce-
dures, the post-transfusion ERO2 values 
did not change in patients with normal 
pre-transfusion ERO2 values. In patients 
with elevated pre-transfusion ERO2 val-
ues, a significant reduction in ERO2 levels 
was noticed after the transfusion. The au-
thors concluded that incorporating ERO2 
into the decision on transfusion therapy 
could substantially reduce post-cardiac 
surgery RBCs transfusions. (24) Seghal et 
al. tried to determine whether transfusion 
practices would have been different if an 
ERO2 ≥ 45% had been used as a transfu-
sion trigger on patients subjected to CABG 
procedures. The authors concluded that 
the use of ERO2 in transfusion algorithms 
could reduce allogeneic blood transfu-
sion. (25) In a study by O’Farrell et al. on 
patients subjected to complex cardiac sur-
gical procedures, a decrease in ERO2 was 
noticed two hours after the administration 
of RBCs if the baseline ERO2 was elevated. 
The study suggests that increased ERO2 
may be a better transfusion trigger than 
decreased Hgb concentrations and that 
using ERO2 in everyday clinical practice 
may reduce unnecessary blood transfu-
sions. In the study, 40% of transfusions 
would have been avoided if elevated ERO2 
was used as the transfusion trigger instead 
of Hgb concentrations. (26) On 58 patients 
admitted to the general ICU, Mung’ayi 
et al. tried to determine the relation be-
tween RBCs transfusions and ERO2, using 
ScVO2 instead of SVO2. The study showed 
that blood transfusion did not significantly 
change ERO2. Changes in Hgb concentra-
tions did not correlate with ERO2 changes 
following blood transfusions. In patients 
with a higher APACHE score, a statistically 
significant relation in the change of ERO2 
following blood transfusion was noticed. A 
subgroup analysis of the patients with pre-
transfusion ERO2 higher than 0.30 yielded 
a mean reduction in ERO2 of 0.055. The 
study results imply that the majority of pa-
tients who were transfused, did not physio-
logically require RBCs, and did not benefit 
from the increased oxygen content. The 
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authors’ comment on the lack of significant 
changes in the ERO2 was that about 60% 
of the patients had a baseline ERO2 below 
0.30. If ERO2 of 0.45 had been the transfu-
sion trigger, then only 3 out of 58 patients 
would have been transfused. (45) Despite 
the fact that blood transfusions may im-
prove physiologic and even global oxygen-
ation parameters in critically ill patients, 
blood circulation to individual organs, 
regional oxygenation and microvascular 
perfusion may be significantly impaired. 
(46) This impairment may be expressed 
particularly when stored RBCs are used. 
On an animal model, Tsai et al. compared 
the effects of fresh and stored RBCs on mi-
crovascular perfusion and DO2 after acute 
isovolemic hemodilution. In comparison 
to fresh RBCs, stored RBCs reduced mi-
crovascular flow and functional capillary 
density, microvascular oxygen extraction 
and the tissue oxygen levels. The authors 
concluded that stored RBCs caused signifi-
cantly malperfused and underoxygenated 
microvasculature, that was not detectable 
on the systemic level. (47) Possible future 
‘physiologic’ transfusion triggers will be 
organ-specific, based on impairment of re-
gional tissue oxygenation. Myocardial tis-
sue oxygenation, estimated by electrocar-
diographic ST-segment changes, cerebral, 
abdominal and muscle tissue oxygenation 
estimated by near infrared spectroscopy or 
in-vivo optical spectroscopy, regional cap-
nography, neuropsychologic and cognitive 
function tests and other techniques have 
already been investigated in a number of 
transfusion therapy studies. (17, 48, 49, 50)
CONCLUSION
Well indicated transfusion therapy will 
improve patients’ clinical outcomes and 
even save lives. The uncritical administra-
tion of blood products will impair patients’ 
primary conditions, cause serious adverse 
effects and unnecessary financial expenses. 
Most transfusion guidelines suggest that a 
combination of Hgb/Htc levels and clini-
cal signs should be used in the decision 
making process for blood transfusions. 
The problem with such indications is that 
clinical evaluation may be misleading in 
severely ill patients, and Hgb levels that 
impair oxygen utilisation cannot be easily 
determined. SVO2 and ERO2 are good in-
dicators that show whether a blood trans-
fusion is really necessary. Whenever possi-
ble, this is what should be used in everyday 
clinical practice. In some patients catego-
ries in the ICU, ScVO2 and ERO2 derived 
from ScVO2 could be used as transfusion 
indicators, provided that clinicians are 
familiar with the specific differences be-
tween ScVO2 and SVO2 in normal and 
critically ill patients. 
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